Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval | Alzheimer's Research & Therapy | Full Text

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval | Alzheimer's Research & Therapy | Full Text

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful effic...

Authors:Martin Tolar, Susan Abushakra, John A. Hey, Anton Porsteinsson and Marwan Sabbagh

Citation:Alzheimer's Research & Therapy 2020 12:95

Content type:Review

 

Published on: 12 August 2020

• ViewFull Text
 
• ViewPDF